Olokizumab  (Synonyms: CDP 6038; OKZ)

Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Olokizumab (from 10 µg/mL; 72 h) inhibits acute phase protein production in primary human hepatocytes, demonstrating its neutralization of IL-6 cis-signaling^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Olokizumab (1-20 mg/kg; i.v.; once a week) significantly reduces arthritis scores, CRP levels, and improves histology and bone erosion scores in a cynomolgus Collagen-induced arthritis model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.94 kDa

1007223-17-7

Liquid

Colorless to light yellow

[Olokizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3(6):e119.  [Content Brief]

  [2]. Shaw S, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.  [Content Brief]

  [3]. Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors & Clinical Investigation, 2016, 3.